In vitro susceptibility of isolates of Francisella tularensis from Turkey

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 5, 2013, Pages 337-341

  Kiliç, Selçuk ^a   Çelebi, Bekir ^a   Acar, Bülent ^a   Ataş, Mehmet ^b  

^a National Tularemia Reference Laboratory   (Turkey)

^b Public Health Laboratory   (Turkey)

Author keywords

Antimicrobial susceptibility; Epsilometer test; Francisella tularensis; Tularemia; Turkey

Indexed keywords

CHLORAMPHENICOL; CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

AMPLICON; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BIOTYPE; EPSILOMETER TEST; FRANCISELLA TULARENSIS; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; TULAREMIA;

ANIMALS; ANTI-BACTERIAL AGENTS; FRANCISELLA TULARENSIS; HUMANS; MICROBIAL SENSITIVITY TESTS; RODENTIA; TULAREMIA; TURKEY; WATER MICROBIOLOGY;

EID: 84876270392     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.751125     Document Type: Article

References (27)

1. World Health Organization. WHO Guidelines on Tularemia. WHO/CDS/EPR/2007.7. Geneva: WHO; 2007.
2. Sjöstedt A. Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations. Ann N Y Acad Sci 2007; 1105: 1-29.
3. Eliasson H, Broman T, Forsman M, Bäck E. Tularemia: current epidemiology and disease management. Infect Dis Clin North Am 2006; 2: 289-311.
4. Tarnvik A, Chu M C. New approaches to diagnosis and therapy of tularemia. Ann N Y Acad Sci 2007; 1105: 378-404.
5. Kudelina RI, Olsufi ev N G. Sensitivity to macrolide antibiotics and lincomycin in Francisella tularensis holarctica. JHyg Epidemiol Microbiol Immunol 1980; 24: 84-91.
6. Sandström G, Sjöstedt A, Forsman M, Pavlovich NV, Mishankin BN. Characterization and classifi cation of strains of Francisella tularensis isolated in the central Asian focus of the Soviet Union and in Japan. JClin Microbiol 1992; 1: 172-5.
7. Enderlin G, Morales L, Jacobs RF, Cross J T. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clin Infect Dis 1994; 19: 42-7.
8. Syrjala H, Schildt R, Raisainen S. In vitro susceptibility of Francisella tularensis to fl uoroquinolones and treatment of tularemia with norfl oxacin and ciprofl oxacin. Eur J Clin Microbiol Infect Dis 1991; 10: 68-70.
9. Johansson A, Berglund L, Gothefors L, Sjostedt A, Tärnvik A. Ciprofl oxacin for treatment of tularemia in children. Pediatr Infect Dis J 2000; 19: 449-53.
10. Johansson A, Berglund L, Sjostedt A, Tärnvik A. Ciprofl oxacin for treatment of tularemia. Clin Infect Dis 2001; 33: 267-8.
11. Meric M, Willke A, Finke EJ, Grunow R, Sayan M, Erdogan S, Gedikoglu S. Evaluation of clinical, laboratory, and therapeutic features of 145 tularemia cases: the role of quinolones in oropharyngeal tularemia. APMIS 2008; 116: 66-73.
12. Tomaso H, Al Dahouk S, Hoefer E, Splettstoesser W, Treu T, Dierich M, Neubauer H. Antimicrobial susceptibilities of Austrian Francisella tularensis holarctica biovar II strains. Int J Antimicrob Agents 2005; 26: 279-84.
13. Yesilyurt M, Kilic S, Celebi B, Celik M, Gul S, Erdogan F, Ozel G. Antimicrobial susceptibilities of Francisella tularensis subsp. holarctica strains isolated from humans in the Central Anatolia region of Turkey. JAntimicrob Chemother 2011; 11: 2588-92.
14. Sjöstedt A, Kuoppa K, Johansson A, Sandström G. The 17 kDa lipoprotein and encoding gene of Francisella tularensis LVS are conserved in 241 strains of Francisella tularensis. Microb Pathog 1992; 13: 243-9.
15. Broekhuijsen M, Larsson P, Johansson A, Bystrom M, Eriksson U, Larsson E, et al. Genome-wide DNA microarray analysis of Francisella tularensis strains demonstrates extensive genetic conservation within the species but identifi es regions that are unique to the highly virulent F. tularensis subsp. tularensis. JClin Microbiol 2003; 7: 2924-31.
16. Huber B, Escudero R, Busse HJ, Seibold E, Scholz HC, Anda P, et al. Description of Francisella hispaniensis sp. nov., isolated from human blood, reclassifi cation of Francisella novicida (Larson et al. 1955) Olsufi ev et al. 1959 as Francisella tularensis subsp. novicida comb. nov. and emended description of the genus Francisella. Int J Syst Evol Microbiol 2010; 60: 1887-96.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Sixteenth informational supplement. CLSI document M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute; 2006.
18. Ikäheimo I, SyrjäläH, Karhukorpi J, Schildt R, Koskela M. In vitro antibiotic susceptibility of Francisella tularensis isolated from humans and animals. JAntimicrob Chemother 2000; 46: 287-90.
19. Eric V, Vaissaire J, Merens A, Hernandez E, Gros C, Le Doujet C, et al. Susceptibility of 71 French isolates of Francisella tularensis subsp. holarctica to eight antibiotics and accuracy of the E test method. JAntimicrob Chemother 2008; 1: 208-10.
20. García del Blanco N, Gutiérrez Martí n CB, de la Puente Redondo VA, Rodríguez Ferri EF. In vitro susceptibility of fi eld isolates of Francisella tularensis subsp. holarctica recovered in Spain to several antimicrobial agents. Res Vet Sci 2004; 76: 195-8.
21. Johansson A, Urich SK, Chu MC, Sjöstedt A, Tärnvik A. In vitro susceptibility to quinolones of Francisella tularensis subspecies tularensis. Scand J Infect Dis 2002; 34: 327-30.
22. Scheel O, Hoel T, Sandvik T, Berdal BP. Susceptibility pattern of Scandinavian Francisella tularensis isolates with regard to oral and parenteral antimicrobial agents. APMIS 1993; 101: 33-6.
23. Urich SK, Petersen JM. In vitro susceptibility of isolates of Francisella tularensis types A and B from North America. Antimicrob Agents Chemother 2008; 6: 2276-8.
24. Aranda EA. Treatment of tularemia with levofl oxacin. Clin Microbiol Infect 2001; 7: 167-8.
25. Scheel O, Reiersen R, Hoel T. Treatment of tularemia with ciprofl oxacin. Eur J Clin Microbiol Infect Dis 1992; 11: 447-8.
26. Harrell RE Jr, Simmons HF. Pleuropulmonary tularemia: successful treatment with erythromycin. South Med J 1990; 83: 1363-4.
27. Westerman EL, McDonald J. Tularemia pneumonia mimicking legionnaires ' disease: isolation of organism on CYE agar and successful treatment with erythromycin. South Med J 1983; 76: 1169-70.